iKnowMed Ranked No. 1 EHR in Oncology/Hematology

Saturday, February 11, 2012 07:48 AM

iKnowMed Electronic Health Record (EHR) System, a product of McKesson Specialty Health and the US Oncology Network, has been named the highest ranked overall EHR vendor for oncology and hematology practices by the 2012 Black Book Rankings Survey. 

Black Book Rankings, a division of Brown-Wilson Group, is a full-service technology and services market research and opinion research company. The survey collected ballot results from more than 80,000 healthcare professionals in North America, including physicians and practice administrators, to find the top performing and most respected EHR vendors for 2012 in four categories—radiology, pathology, oncology and cardiology.

Out of 20 EHR vendors in the oncology category, iKnowMed received “overwhelming satisfaction and exceeds expectations” rankings in all 18 key performance areas and received the highest ranking in 12 of the 18 areas with an average score of 9.62 out of 10.

“Receiving top honors is significant because it... proves that an EHR developed by oncologists for oncologists really best supports their specialized needs,” said Mark A. Sitarik, M.D., medical director for iKnowMed.

iKnowMed is a web-based oncology-specific EHR that has achieved 2011/2012 Complete EHR Certification by an ONC-ATCB in accordance with Meaningful Use criteria. Clinical content includes point-of-care decision support with detailed cancer diagnosis and staging content, and a regimen library of more than 400 up-to-date cancer regimens. iKnowMed EHR supports clinical trial accruals for new and existing patients, provides access to level I pathways or evidence-based treatment guidelines, has integrated ePrescribing capabilities, a charge interface and has been proven to improve gross charge capture ranging from $35,000 to $86,000 per oncologist.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs